Diagnostic Innovations Driving Esoteric Testing Market Growth: Advancements in Melanoma and Preeclampsia Testing

Quest Diagnostics Introduces MelaNodal Predict™ for Personalized Melanoma Treatment

Quest Diagnostics, a prominent name in diagnostic information services, has unveiled MelaNodal Predict™, an innovative predictive gene expression test designed to tailor treatment decisions for melanoma patients. The test, which uses cutting edge technology produced in collaboration with SkylineDx and the Mayo Clinic, is currently available for order through Quest Diagnostics and Dermpath Diagnostics. 

MelaNodal Predict™ is a combination of tumor age and tumour density analysis with advanced gene expression profiling, which allows healthcare professionals to identify patients at different risk for nod metastasis. In addition, healthcare providers may prevent patients from unnecessarily invasive procedures such as sentinel lymph node biopsy by incorporating SkylineDx's technology into Quest's extensive expertise and nationwide coverage.

The launch of MelaNodal Predict™ marks a significant stride in personalized medicine for melanoma treatment, offering clinicians actionable insights to optimize patient care and outcomes.

Labcorp Introduces FDA-Cleared Blood Test for Severe Preeclampsia Risk Assessment

A new FDA cleared Blood Test to assess the risk of serious preeclampsia during pregnancy has been launched by Labcorp, a leading global provider of laboratory services. Developed by Thermo Fisher Scientific and recognized as one of TIME Magazine's Best Inventions of 2023, the test measures two angiogenic biomarkers—sFlt-1 and PlGF—associated with preeclampsia.

The test, validated by a PRAECIS study involving over 1,000 pregnant women, has been shown to provide clinicians with a ratio of biomarkers that can help identify patients at risk for developing severe preeclampsia in 2 weeks. Pregnant women who test positive can benefit from enhanced surveillance and expedited care, mitigating potential complications.

Market Projection for Esoteric Testing

The market for Esoteric Testing is rapidly growing and is projected to reach USD 62.43 billion by 2032, up from USD 27.31 billion in 2023, with a CAGR of 10.89 %. This surge is driven by the to the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions. Moreover, strong financial resources from both public and private sectors coupled with continued technological progress are driving the market expansion. As the demand for advanced diagnostic solutions continues to soar, stakeholders anticipate sustained innovation and collaboration to address evolving healthcare needs effectively.